IDP Pharma

IDP Pharma is a private, pre-clinical biotech focused on developing first-in-class drugs for intrinsically disordered proteins (IDPs), which represent a vast, untapped therapeutic target space linked to major diseases like cancer. The company's core innovation is the INTRAMETICS™ platform, which designs advanced peptidomimetics capable of directly binding to and degrading IDPs, overcoming traditional druggability challenges. With a seasoned leadership team and scientific advisory board, IDP Pharma is positioning itself at the forefront of a new modality in drug discovery, aiming to open therapeutic routes for conditions with high unmet medical need.

The INTRAMETICS™ platform designs next-generation peptidomimetics to directly target and degrade Intrinsically Disordered Proteins (IDPs), a historically undruggable class of proteins, using a protein-centric approach that counters all deregulation mechanisms.

Total raised: $7.3M

IDP Pharma's main competition comes from indirect standard-of-care therapies and emerging protein degradation technologies (PROTACs) that struggle with IDPs. Its key differentiation is the specialized INTRAMETICS platform and peptidomimetic expertise explicitly focused on the direct engagement and degradation of IDPs, positioning it as a potential first-mover in this niche.